Wockhardt, a pharmaceutical and biotechnology company headquartered in India, has finally secured US Food and Drug Administration's (USFDA) tentative approval for marketing Tamsulosin Hydrochloride capsules.

The drug is the generic version of US-based Boehringer Ingelheim's Flomax, which used for treating non-cancerous enlargement of prostate, medically termed as benign prostatic hyperplasia.

Reports suggest that Boehringer Ingelheim's patent on Flomax is set to expire on 27 April 2010, due to which Wockhardt will launch the product immediately after the expiry of the patent.

As per IMS data, the total market size for the drug in US stand at about $1.65 million.

On the back of positive announcement, the shares of Wockhardt closed at Rs 195, up 7.57% compared to its previous close.